Intuit Inc. (NASDAQ: INTU) was reiterated as Overweight and its price target was raised to $285 from $275 (versus a $267.78 close) at KeyBanc Capital Markets.
Kura Oncology Inc. (NASDAQ: KURA) was started with an Overweight rating and a $24 price target (versus a $14.70 close) at Barclays.
L Brands Inc. (NYSE: LB) was raised to Outperform from Market Perform with a $17 price target (versus a $12.04 close) at BMO Capital Markets. It had a $16.21 consensus price target.
ONEOK Inc. (NYSE: OKE) was downgraded to Neutral from Outperform at Credit Suisse.
Owens & Minor Inc. (NYSE: OMI) was downgraded to Neutral from Outperform at Robert W. Baird
Peloton Interactive Inc. (NASDAQ: PTON) was reiterated as Buy and its price objective was raised to $41 from $36 (versus a $33.90 close) at BofA Securities. The consensus price target was $38.48.
Replimune Group Inc. (NASDAQ: REPL) was started with an Overweight rating and a $21 price target (versus a $15.93 close) at Barclays.
Salesforce.com Inc. (NYSE: CRM) was started with a Sell rating and a $120 price target at Rosenblatt. Shares closed up over 3% at $161.47 ahead of this call and had a $194.38 consensus price target. They were indicated up 0.2% on Tuesday.
Shake Shack Inc. (NYSE: SHAK) was reiterated as Hold but its price target was raised to $55 from $50 (versus a $52.77 close) at SunTrust Robinson Humphrey. Wedbush Securities reiterated its Neutral rating, along with a $50 price target.
TripAdvisor Inc. (NASDAQ: TRIP) was maintained with a Buy rating but its price target was lowered to $26 from $39 (versus an $18.72 close) at Needham.
Tyson Foods Inc. (NYSE: TSN) was down 7.8% at $55.32 after earnings on Monday. BofA Securities downgraded it to Neutral from Buy and cut its price objective to $60 from $70.
Wells Fargo & Co. (NYSE: WFC) was downgraded to Underweight from Neutral with a $25 price target at Atlantic Equities.
Workday Inc. (NASDAQ: WDAY) was started with a Sell rating and a $110 price target at Rosenblatt. The stock closed up 1.2% at$148.47 ahead of the call, with a $175.16 consensus price target.
Y-mAbs Therapeutics Inc. (NASDAQ: YMAB) was started as Overweight with a $44 price target (versus a $33.80 close) at Barclays.
The BofA Securities analysts have a Yield Advantage group of stocks that are outperforming other high dividend shares. We selected five from the list with big dividends and a Buy rating.
Monday’s top analyst upgrades and downgrades included AON, Cognizant Technology Solutions, Dow, PayPal, PG&E, PNC Financial Services, Qualcomm, Shopify, Tesla, Valero Energy, Walt Disney, Wells Fargo and more.
Sponsored: Tips for Investing
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.